Fluoxetine in Parkinson's disease

Movement Disorders

Volumn 11, Issue 5, 1996, Pages 581-582

  Simons, J A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; FLUOXETINE; LEVODOPA; PAROXETINE; SELEGILINE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DETERIORATION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREMOR;

EID: 0029791971     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110517     Document Type: Short Survey

References (2)

1. Jansen Steur ENH. Increase in Parkinson disability after fluoxetine medication. Neurology 1993;43:211-213.
2. Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology 1994; 44:2406.